Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

16.12.25 05:35 Uhr

Werte in diesem Artikel
Aktien

46,28 USD -93,04 USD -66,78%

2,86 EUR 0,08 EUR 2,88%

Aristotle Capital Boston disclosed in a November 14 SEC filing that it sold 503,122 shares of Supernus Pharmaceuticals (NASDAQ:SUPN), contributing to a reduction in its position by about $10.9 million.According to a Securities and Exchange Commission (SEC) filing dated November 14, Aristotle Capital Boston reduced its holdings in Supernus Pharmaceuticals (NASDAQ:SUPN) by 503,122 shares in the third quarter. The fund’s overall position decreased to 305,273 shares with a reported value of $14.6 million as of September 30. The estimated value of shares sold was approximately $10.9 million.Supernus represents about 0.75% of 13F AUM as of September 30.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Ausgewählte Hebelprodukte auf AS ONE

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AS ONE

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: MotleyFool

Nachrichten zu AS ONE CORP

Wer­bung